Canada's new public-sector payment system is still years away from being implementedJoint Stock Company Kaspi.kz Announcement: If You Have Suffered Losses in Joint Stock Company Kaspi.kz (NASDAQ: KSPI), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Kylian Mbappe’s spot-kick woe goes on as Real Madrid lose at Athletic Bilbao
Celebrating resilience and innovation: Highlights from the 2024 Smart50 AwardsPlayers must be assigned female at birth or have transitioned to female before going through male puberty to compete in LPGA tournaments or the eight USGA championships for females under new gender policies published Wednesday. The policies, which begin in 2025, follow more than a year of study involving medicine, science, sport physiology and gender policy law. The updated policies would rule out eligibility for Hailey Davidson, who missed qualifying for the U.S. Women's Open this year by one shot and came up short in LPGA Q-school. Davidson, who turned 32 on Tuesday, began hormone treatments when she was in her early 20s in 2015 and in 2021 underwent gender-affirming surgery, which was required under the LPGA's previous gender policy. She had won this year on a Florida mini-tour called NXXT Golf until the circuit announced in March that players had to be assigned female at birth. “Can't say I didn't see this coming,” Davidson wrote Wednesday on an Instagram story. “Banned from the Epson and the LPGA. All the silence and people wanting to stay ‘neutral’ thanks for absolutely nothing. This happened because of all your silence.” LPGA commissioner Mollie Marcoux Samaan, who is resigning in January, said the new gender policy "is reflective of an extensive, science-based and inclusive approach." By making it to the second stage of Q-school, Davidson would have had very limited status on the Epson Tour, the pathway to the LPGA. The LPGA and USGA say their policies were geared toward being inclusive of gender identities and expression while striving for equity in competition. The LPGA said its working group of experts advised that the effects of male puberty allowed for competitive advantages in golf compared with players who had not gone through puberty. “Our policy is reflective of an extensive, science-based and inclusive approach,” said LPGA Commissioner Mollie Marcoux Samaan, who announced Monday that she is resigning in January. "The policy represents our continued commitment to ensuring that all feel welcome within our organization, while preserving the fairness and competitive equity of our elite competitions.” Mike Whan, the former LPGA commissioner and now CEO of the USGA, said it developed the updated policy independently and later discovered it was similar to those used by swimming, track and field, and other sports. United States Golf Association CEO Mike Whan said the new policy will prevent anyone from having "a competitive advantage based on their gender." “It starts with competitive fairness as the North star,” Whan said in a telephone interview. “We tried not to get into politics, or state by state or any of that stuff. We just simply said, ‘Where would somebody — at least medically today — where do we believe somebody would have a competitive advantage in the field?’ And we needed to draw a line. “We needed to be able to walk into any women's event and say with confidence that nobody here has a competitive advantage based on their gender. And this policy delivers that.” The “Competitive Fairness Gender Policy” for the USGA takes effect for the 2025 championship season that starts with the U.S. Women's Amateur Four-Ball on May 10-14. Qualifying began late this year, though there were no transgender players who took part. “Will that change in the years to come as medicine changes? Probably,” Whan said. “But I think today this stacks up.” The LPGA “Gender Policy for Competition Eligibility” would apply to the LPGA Tour, Epson Tour, Ladies European Tour and qualifying for the tours. Players assigned male at birth must prove they have not experienced any part of puberty beyond the first stage or after age 12, whichever comes first, and then meet limitation standards for testosterone levels. The LPGA begins its 75th season on Jan. 30 with the Tournament of Champions in Orlando, Florida. Buffalo Bills quarterback Josh Allen, foreground right, dives toward the end zone to score past San Francisco 49ers defensive end Robert Beal Jr. (51) and linebacker Dee Winters during the second half of an NFL football game in Orchard Park, N.Y., Sunday, Dec. 1, 2024. (AP Photo/Adrian Kraus) South Carolina guard Maddy McDaniel (1) drives to the basket against UCLA forward Janiah Barker (0) and center Lauren Betts (51) during the first half of an NCAA college basketball game, Sunday, Nov. 24, 2024, in Los Angeles. (AP Photo/Eric Thayer) Mari Fukada of Japan falls as she competes in the women's Snowboard Big Air qualifying round during the FIS Snowboard & Freeski World Cup 2024 at the Shougang Park in Beijing, Saturday, Nov. 30, 2024. (AP Photo/Andy Wong) LSU punter Peyton Todd (38) kneels in prayer before an NCAA college football game against Oklahoma in Baton Rouge, La., Saturday, Nov. 30, 2024. LSU won 37-17. (AP Photo/Gerald Herbert) South Africa's captain Temba Bavuma misses a catch during the fourth day of the first Test cricket match between South Africa and Sri Lanka, at Kingsmead stadium in Durban, South Africa, Saturday, Nov. 30, 2024. (AP Photo/Themba Hadebe) Philadelphia Eagles running back Saquon Barkley, left, is hit by Baltimore Ravens cornerback Marlon Humphrey, center, as Eagles wide receiver Parris Campbell (80) looks on during a touchdown run by Barkley in the second half of an NFL football game, Sunday, Dec. 1, 2024, in Baltimore. (AP Photo/Stephanie Scarbrough) Los Angeles Kings left wing Warren Foegele, left, trips San Jose Sharks center Macklin Celebrini, center, during the third period of an NHL hockey game Monday, Nov. 25, 2024, in San Jose, Calif. (AP Photo/Godofredo A. Vásquez) Olympiacos' Francisco Ortega, right, challenges for the ball with FCSB's David Miculescu during the Europa League league phase soccer match between FCSB and Olympiacos at the National Arena stadium, in Bucharest, Romania, Thursday, Nov. 28, 2024. (AP Photo/Andreea Alexandru) Brazil's Botafogo soccer fans react during the Copa Libertadores title match against Atletico Mineiro in Argentina, during a watch party at Nilton Santos Stadium, in Rio de Janeiro, Saturday, Nov. 30, 2024. (AP Photo/Bruna Prado) Seattle Kraken fans react after a goal by center Matty Beniers against the San Jose Sharks was disallowed due to goaltender interference during the third period of an NHL hockey game Saturday, Nov. 30, 2024, in Seattle. The Sharks won 4-2. (AP Photo/Lindsey Wasson) New York Islanders left wing Anders Lee (27), center, fight for the puck with Boston Bruins defensemen Parker Wotherspoon (29), left, and Brandon Carlo (25), right during the second period of an NHL hockey game, Wednesday, Nov. 27, 2024, in Elmont, N.Y. (AP Photo/Julia Demaree Nikhinson) Jiyai Shin of Korea watches her shot on the 10th hole during the final round of the Australian Open golf championship at the Kingston Heath Golf Club in Melbourne, Australia, Sunday, Dec. 1, 2024. (AP Photo/Asanka Brendon Ratnayake) Mathilde Gremaud of Switzerland competes in the women's Freeski Big Air qualifying round during the FIS Snowboard & Freeski World Cup 2024 at the Shougang Park in Beijing, Friday, Nov. 29, 2024. (AP Photo/Andy Wong) Lara Gut-Behrami, of Switzerland, competes during a women's World Cup giant slalom skiing race, Saturday, Nov. 30, 2024, in Killington, Vt. (AP Photo/Robert F. Bukaty) New York Islanders goaltender Ilya Sorokin cools off during first period of an NHL hockey game against the Boston Bruins, Wednesday, Nov. 27, 2024, in Elmont, N.Y. (AP Photo/Julia Demaree Nikhinson) Brazil's Amanda Gutierres, second right, is congratulated by teammate Yasmin, right, after scoring her team's first goal during a soccer international between Brazil and Australia in Brisbane, Australia, Thursday, Nov. 28, 2024. (AP Photo/Pat Hoelscher) Las Vegas Raiders tight end Brock Bowers (89) tries to leap over Kansas City Chiefs cornerback Joshua Williams (2) during the first half of an NFL football game in Kansas City, Mo., Friday, Nov. 29, 2024. (AP Photo/Ed Zurga) Luiz Henrique of Brazil's Botafogo, right. is fouled by goalkeeper Everson of Brazil's Atletico Mineiro inside the penalty area during a Copa Libertadores final soccer match at Monumental stadium in Buenos Aires, Argentina, Saturday, Nov. 30, 2024. (AP Photo/Natacha Pisarenko) England's Alessia Russo, left, and United States' Naomi Girma challenge for the ball during the International friendly women soccer match between England and United States at Wembley stadium in London, Saturday, Nov. 30, 2024. (AP Photo/Kirsty Wigglesworth) Minnesota Vikings running back Aaron Jones (33) reaches for an incomplete pass ahead of Arizona Cardinals linebacker Mack Wilson Sr. (2) during the second half of an NFL football game Sunday, Dec. 1, 2024, in Minneapolis. (AP Photo/Abbie Parr) Melanie Meillard, center, of Switzerland, competes during the second run in a women's World Cup slalom skiing race, Sunday, Dec. 1, 2024, in Killington, Vt. (AP Photo/Robert F. Bukaty) Houston Rockets guard Jalen Green goes up for a dunk during the second half of an Emirates NBA cup basketball game against the Minnesota Timberwolves, Tuesday, Nov. 26, 2024, in Minneapolis. (AP Photo/Abbie Parr) Gold medalists Team Netherlands competes in the Team Sprint Women race of the ISU World Cup Speed Skating Beijing 2024 held at the National Speed Skating Oval in Beijing, Sunday, Dec. 1, 2024. (AP Photo/Ng Han Guan) Sent weekly directly to your inbox!
SAN DIEGO , Dec. 13, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved CRENESSITYTM (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH), a rare, serious and lifelong genetic condition involving the adrenal glands. CRENESSITY, a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist, is the first and only classic CAH treatment that directly reduces excess adrenocorticotropic hormone (ACTH) and downstream adrenal androgen production, allowing for glucocorticoid dose reduction. It is a breakthrough in the treatment landscape for classic CAH. "For the last three decades, Neurocrine Biosciences, together with our late founder, Wylie W. Vale , has conducted groundbreaking research uncovering the critical role of corticotropin-releasing factor and its receptor, CRF 1 , in the pathophysiology of congenital adrenal hyperplasia," said Kyle W. Gano , Ph.D., Chief Executive Officer, Neurocrine Biosciences. "The approval of CRENESSITY is a significant milestone for the CAH community, and we are grateful to the individuals who participated in our clinical trials, including their families and caregivers, and to the clinical investigators who helped advance a new therapy and class of medicines." "Patients and families struggle to achieve balance between managing the symptoms of CAH and the side effects or complications of treatment with high-dose steroids, which may impact quality of life," said Dina Matos , Executive Director, CARES Foundation. "We are grateful to Neurocrine Biosciences for engaging with our community throughout the drug development process to understand our needs and ultimately providing this new medication that can help reduce excess adrenal androgens and the need for high-dose steroid treatment for individuals living with CAH." CRENESSITY is expected to be commercially available in approximately one week. The medication will be provided through PANTHERx Rare, a specialty pharmacy, to centralize and simplify CRENESSITY prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a free, comprehensive assistance program created for patients, caregivers and healthcare providers. It offers a range of options to make sure patients have everything they need to begin and continue taking CRENESSITY. A dedicated Care Coordinator, backed by a team, is available to help patients and caregivers navigate the insurance process and identify appropriate financial assistance options. Most patients will pay $10 or less per month for CRENESSITY*. For more information, visit www.NBIaccess.com/crenessity or call 1-855-CRNSITY (276-7489) Monday-Friday 8 am-8 pm ET . *Additional terms and conditions apply. CAHtalyst TM Clinical Program Overview: The FDA approval is supported by the largest-ever clinical trial program of classic CAH, the CAHtalyst Pediatric and Adult Phase 3 global registrational studies. CAHtalyst Phase 3 data results in pediatric and adult patients with classic CAH were published in The New England Journal of Medicine . "The clinical results across both CAHtalyst studies support the efficacy and safety profile of CRENESSITY and its ability to reduce the overproduction of adrenal androgens, allowing for a meaningful reduction in glucocorticoid dosage, while maintaining or enhancing control of these androgens," said Richard Auchus , M.D., Ph.D., Professor, University of Michigan Health, Principal Investigator. "Chronic treatment with supraphysiologic glucocorticoids can cause a number of short- and long-term health consequences, such as obesity, hypertension and osteoporosis, so the ability for patients with CAH to lower their glucocorticoid dose to a more physiologic level can have profound benefits." In both CAHtalyst studies, CRENESSITY enabled lower steroid doses and decreased androgen levels. Phase 3 CAHtalyst Pediatric Study: Phase 3 CAHtalyst Adult Study: CRENESSITY was well tolerated with few treatment-related adverse events in both CAHtalyst studies. Pediatric and adult patients taking CRENESSITY had no treatment-related serious adverse events. Adrenal insufficiency and crisis are risks of living with CAH that CRENESSITY does not address and can occur when a patient's GC dose is too low. In the CAHtalyst Pediatric study, there were no cases of adrenal crisis among patients taking CRENESSITY or placebo. In the CAHtalyst Adult study, two patients (1.6%) taking CRENESSITY experienced adrenal crisis. No patients on placebo experienced adrenal crisis. However, one patient (1.7%) on placebo experienced adrenal insufficiency. Patients should work with their healthcare provider to manage GC dosing while taking CRENESSITY. For more information about CRENESSITY, visit Crenessity.com . About Congenital Adrenal Hyperplasia Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens, which are essential for life. Approximately 95% of CAH cases are caused by variants of the CYP21A2 gene that leads to deficiency of the enzyme 21-hydroxylase (21-OH). Severe deficiency of this enzyme leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in salt wasting, dehydration and even death. Historically, exogenous glucocorticoids (GCs) have been used not only to correct the endogenous cortisol deficiency, but doses used are higher than cortisol replacement needed (supraphysiologic) to lower the levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at high doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with high-dose GCs may have psychological and cognitive impact, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, testicular rest tumors in males and fertility issues in both sexes. About The CAHtalystTM Studies The Phase 3 CAHtalystTM global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients. The CAHtalyst Pediatric study included 103 pediatric patients aged four to 17 years. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved. The CAHtalyst Adult study included 182 adult patients aged 18 to 58 years. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved. Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing. About CRENESSITYTM (crinecerfont) CRENESSITYTM is a potent and selective, oral corticotropin-releasing factor type 1 receptor (CRF 1 ) antagonist developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF 1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol. CRENESSITY comes in capsules and an oral solution. The capsule formulation is available in 50 mg and 100 mg doses. The oral solution is available as a 50 mg/mL strength formulation. For adults 18 years and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement. Important Information Approved Uses CRENESSITY (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). IMPORTANT SAFETY INFORMATION Do not take CRENESSITY if you: Are allergic to crinecerfont, or any of the ingredients in CRENESSITY. CRENESSITY may cause serious side effects, including : Allergic Reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY. Risk of Sudden Adrenal Insufficiency or Adrenal Crisis With Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine. Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take , including prescription and over-the counter medicines, vitamins, and herbal supplements. The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain. The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nose bleeds. These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules and as an oral solution of 50 mg/mL. Please see full Prescribing Information About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (formerly Twitter) and Facebook . (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY and CAHtalyst are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency; the value and benefits CRENESSITY brings to patients with CAH; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; the degree and pace of market uptake of CRENESSITY; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024 . Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CP-CFT-US-0070 12/2024 View original content to download multimedia: https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-crenessity-crinecerfont-a-first-in-class-treatment-for-children-and-adults-with-classic-congenital-adrenal-hyperplasia-302331772.html SOURCE Neurocrine Biosciences, Inc.Manchester United manager Ruben Amorim hailed Arsenal as one of the best set-piece teams he has ever faced following the 2-0 defeat at Arsenal. The Gunners took two points out of Liverpool’s lead at the summit of the Premier League after Jurrien Timber and William Saliba struck in the second half – both from corners – to condemn Amorim to his first defeat as United boss. The hosts’ second-half strikes took their goals-from-corners tally to 22 since the start of last season – a statistic that is unmatched by any other team in the division. Asked if Arsenal are one of the best teams he has come up against on corners, Amorim replied: “If you follow the Premier League for a long time you can see that. “They are also big players and you see every occasion when (Gabriel) Martinelli and (Bukayo) Saka have one-on-ones, a lot of times they go outside and they cross, and they know that if the cross goes well, they can score, and if it is a corner they can score, too, so we have to be better on that. “You have seen in all Arsenal games that every team have had problems with that (corners). And the difference today was the set-pieces. “You see a goal and then the momentum changed, and it is really hard for us to take the full control of the game after that.” Timber leaned into Rasmus Hojlund at the front post before diverting Declan Rice’s set-piece into the back of Andre Onana’s net after 54 minutes to send Arsenal into the lead. Thomas Partey’s header from Saka’s corner then deflected in off Saliba’s shoulder with 17 minutes left. Arteta and the club’s set-piece guru Nicolas Jover embraced on the touchline as Amorim was left with his head in his hands. The Arsenal supporters cheered raucously every time they won a corner – landing 13 in all without reply. However, Arteta moved to play down the significance of Arsenal’s set-piece threat. “We need that, but we want to be very dangerous and very effective from every angle and every phase of play,” said Arteta. “Today we could have scored from open play like we did against West Ham and Sporting. Last year we scored the most goals in the history of this football club. Arsenal have won four consecutive Premier League matches against Man Utd for the first time ever! 💫 pic.twitter.com/biv1kvsJEP — Premier League (@premierleague) December 4, 2024 “Not because of only set-pieces, but because of a lot of things that we have. We want to create individual and magic moments, too.” Arsenal’s win against United – the first time they have recorded four victories in a row against the Red Devils in the league – was their fourth in succession since the international break. They will head to Fulham on Sunday bidding to keep the momentum going. Arteta continued: “The will to win is there. We try our best to do that. We won four in a row, but it doesn’t matter. We have to go to Fulham now, try to be better than them and try win the game. “It’s every three days that we play. It’s a crazy schedule. We’re going to need everybody and to mentally be very strong.” We do not moderate comments, but we expect readers to adhere to certain rules in the interests of open and accountable debate.Donald Trump Calls On Feds To Either Explain The Mystery Drones Or Shoot Them Down
Kylian Mbappe’s spot-kick woe goes on as Real Madrid lose at Athletic BilbaoDETROIT — The auto industry has an addiction. It’s a “capital junkie” that’s been on a yearslong binge of unprecedented spending on all-electric and autonomous vehicles. And now, it’s waking up from the bender and entering rehab. Automakers from Detroit to Japan and Germany are attempting to lower costs and reduce expenses amid economic concerns, billions of dollars wasted on self-driving vehicles and a prolonged, if not uncertain, return on investment in EVs amid slower-than-expected adoption. Those issues come in addition to weakening consumer demand, higher commodity costs, and some Wall Street analysts sounding the alarm about global automotive sales and profits peaking, as China’s industry continues to expand. General Motors and Ford Motor are cutting billions in fixed costs, including laying off thousands of workers, while other automakers such as Nissan Motor , Volkswagen Group and Chrysler parent Stellantis are taking even more drastic measures to reduce headcounts and trim spending. “Western [automakers] are increasingly focusing on capital efficiency, meaning likely lower spending, more collaboration, and restructured EV portfolios to prioritize profits,” Morgan Stanley analyst Adam Jonas said in a September investor note. The automotive industry is a global web of companies producing tens of thousands of parts to assemble a new vehicle. It requires significant capital investment every time an automaker launches a new product or updates current models, causing a spending ripple effect throughout the global supply chain. But in recent years, automakers have put such investments in overdrive with self-driving and electric vehicles. Companies invested tens of billions of dollars into the technologies, most with little to no short- to midterm returns on their investments. Research and development costs, as well as capital spending for the top 25 automotive companies, have increased 33% from roughly $200 billion in 2015 to $266 billion in 2023, according to auto consulting firm AlixPartners. Such costs for GM increased about 62% from 2015 to 2023, to $20.6 billion (excluding sold European operations), despite a 38% drop in global sales during that time. That compares with other increases during that timeframe of 42% for Volkswagen; 37% for Toyota Motor; 27% for Fiat Chrysler’s successor Stellantis; and 18% for Ford. EV startups Rivian Automotive and Lucid Group have burned through $16 billion and $8.8 billion, respectively, in free cash flow since 2022. Both companies are attempting to ramp up vehicle production and narrow their losses. It’s not the first time the auto industry has blown through money to then attempt quickly to cut costs. These kinds of periods happen in cyclical industries such as autos, but could the spending have potentially been avoided — or at least alleviated — this time around? Capital junkie The latest cost-cutting cycle comes nearly a decade after an infamous Wall Street presentation by late-Fiat Chrysler CEO Sergio Marchionne called “Confessions of a Capital Junkie.” The April 2015 report highlighted the industry’s massive capital spending on overlapping or niche products that Marchionne was convinced could be solved through consolidation and shared capital spending. The report, made by Marchionne amid failed merger attempts with Fiat Chrysler that included GM, has reemerged as automakers cut costs and announce tie-ups between companies such as Volkswagen and Rivian Automotive as well as GM and Hyundai Motor to share costs. “We believe the concepts within this deck [are] highly insightful and as relevant today as ever,” Jonas said in a November 2023 investor note invoking Marchionne’s junkie manifesto, which he has continued to reference. 'The Sergio Quotient' Using a measurement called “The Sergio Quotient,” Jonas points out that the average S&P 500 company spends its market cap in capex plus research and development in about 50 years. GM and Ford spend their market cap in 1.9 and 2.6 years, respectively. Only Volkswagen, at 1.8 years, was lower than GM among traditional automakers. Toyota was the best suited, at 14.4 years. As of September, Ford and GM ranked 402 and 403 out of 406 nonfinancial companies in the S&P 500 regarding their capital spend compared with their market cap. Former Ford executive Joe Hinrichs brought up Marchionne’s 2015 manifesto during an automotive conference this summer, condemning the industry for its capital waste. “The auto industry is famous for destroying capital. That’s a bad thing,” said Hinrichs, now CEO of railroad company CSX . “If you waste billions of dollars on autonomous vehicles or billions of dollars on electrification, you should be held accountable. That’s shareholder money.” Most capital spending by automakers isn’t wasted, but the industry isn’t as efficient as other sectors, with minimal return on invested capital. The ROIC of traditional, mainstream automakers is roughly seven or less, while tech companies such as Google parent Alphabet are at roughly 22, according to FactSet. “We’ve seen major CapEx spend with extended ROIs, given the slowdown ... and low utilization in manufacturing plants,” said Rebecca Evans, a principal at management consulting firm Roland Berger . “We have been looking extensively at cost.” In particular, automakers have not seen ROIC on autonomous vehicles and EVs. GM continues to invest in its embattled autonomous vehicle unit Cruise despite already spending more than $10 billion on it since acquiring the company in 2016. Ford also has wasted billions of dollars on warranty and recall costs as well as strategy shifts. It recently canceled production of a three-row electric SUV after significant development cost the automaker roughly $1.9 billion in expenses and cash expenditures. That included $400 million for the write-down of certain product-specific manufacturing assets. Rehab After years of spending, Nissan, Volkswagen and Stellantis are conducting massive business restructurings that include layoffs, production cuts and other cost-saving measures. Others such as Ford, GM, and EV startups Lucid and Rivian are attempting to lower costs but their efforts are not as severe as the others. “Have we got to cut costs with every car we’re making? Absolutely,” Lucid CEO Peter Rawlinson told CNBC in October, citing the company’s cost-cutting task force. “We’re working assiduously on that.” Volkswagen is in the midst of a massive cost-cutting program that uncharacteristically involves layoffs and potential plans to shutter plants in its home country of Germany. VW Chairman and CEO Oliver Blume said in an interview published earlier this month that such actions are needed to remedy years of ongoing problems at the German carmaker, which reportedly expects to spend 900 million euros ($975.06 million) to execute the turnaround. “The weak market demand in Europe and significantly lower earnings from China reveal decades of structural problems at VW,” Blume told German paper Bild am Sonntag, according to Reuters . The rise of Chinese automakers has been eating away at the profits of traditional automakers such as VW, GM and others that were once dominant players in China — the world’s largest car market that has quickly moved from being a consumer of vehicles to exporter. Nissan, Honda and BMW, among others, also blamed declines in China for missing earnings expectations or restructuring needs. GM, which has raked in billions from China, is restructuring operations there, including attempting to renegotiate with its major Chinese partner, SAIC. While losing ground in China, GM has been among the most aggressive in spending on EVs and self-driving vehicles. But, to its credit, remains highly profitable and had roughly $27 billion of free cash flow at the end of the third quarter. It remains one of the standouts in balancing investment and cost-cutting efforts, while remaining profitable. GM CFO Paul Jacobson on Wednesday reconfirmed plans for the automaker to level capex to around $11 billion going forward. “What we’ve established over the last couple of years, I think, is a pretty disciplined track record of capital expenditures,” Jacobson said during a Barclays conference . “You want to be in an organization that has more ideas than it can fund. Our job is to allocate that and prioritize it.” Partnerships Newer automakers such as Rivian and Lucid are cutting costs and raising capital to stay afloat as the companies continue to lose tens of thousands of dollars on each EV they sell. Lucid’s largest shareholder, Saudi Arabia’s Public Investment Fund, has invested billions of dollars into the company, while Rivian has teamed up with Volkswagen for an up to $5.8 billion software deal , which is expected to close by the end of this year. GM and Hyundai this summer entered into an agreement to explore “future collaboration across key strategic areas” in an effort to reduce capital spending and increase efficiencies. The companies have not announced any actions since then. Marchionne argued such partnerships were effective but not enough going forward. He said companies could save billions of dollars annually in capital by sharing costs involving commoditized parts such as transmissions, standardized safety equipment and advanced driver assistance systems. “It’s fundamentally immoral to allow for that waste to continue unchecked,” Marchionne said in the three-hour conference call with global industry analysts in 2015. “Something needs to give. It cannot continue like this.” Some things have changed, but there have not been large systemic shifts. Major automotive industry mergers and joint ventures don’t always result in long-term successes. Many fall apart before producing significant results. Both VW and Rivian have experienced such failures with Ford in recent years. Rivian and the Detroit automaker canceled plans to codevelop EVs two years after Ford took a 12% stake in the startup in 2019. Around that time, VW also announced a $2.6 billion deal with Ford for autonomous vehicles that didn’t pan out. Stellantis Stellantis — formed through the merger of Fiat Chrysler and French automaker PSA Groupe in January 2021 — has proven that not all mergers enacted to produce scale guarantee a profitable company. After a record profit last year, the company has struggled in 2024. While Stellantis CEO Carlos Tavares has touted achieving roughly $9 billion in cost reductions following the merger, the automaker has mismanaged the U.S. market — its prime cash generator — with a lack of investment in new or updated products, historically high prices and extreme cost-cutting measures. When asked by Bernstein analyst Daniel Roeska about Stellantis not performing to “capital junkie” standards despite the massive merger, Tavares said the company achieved the scale needed to be more efficient but it’s still working on a product blitz and correcting mistakes in North America . Tavares said Stellantis remains more profitable than Fiat Chrysler and PSA were on their own. He also cited impacts of “regulatory chaos,” a reference to U.S. and Europe standards for EVs and emissions. “Stellantis is the concrete expression of the scale that you need to have to use the resources of your shareholders in a meaningful way. So, that’s what we did. FCA was too small,” Tavares said when discussing first-half results in July. “PSA was too small. Stellantis has the right scale. That’s an answer that I’m sure Sergio would recognize.”World Children’s Day... Enhancing children’s rights to ensure better future
As Trump prepares to take office, ports and dockworkers are facing down a new strikeCreating gender awareness among male children will reduce domestic violence – Effah-Chukwuma
Forget Main Street Capital, 12%-Yielding Capital Southwest Is The Better BuyWho was Brian Thompson, the CEO of UnitedHealthcare fatally shot in Manhattan?
Canada's new public-sector payment system is still years away from being implementedIt's the Friday before Black Friday, and Walmart is kicking off the weekend with an early Black Friday sale. While Walmart's official sale starts Monday at noon, the retailer has early you can shop for today. You can find record-low prices on best-selling kitchen appliances, Apple devices, TVs, vacuums, clothing and toys. • As TechRadar's deals editor, with seven years of experience writing about Black Friday an avid Walmart shopper, I've analyzed this weekend's sale and hand-picked the 21 best deals. I selected the offers based on price, popularity, and sheer value from brands like Apple, Ninja, LG, and Dyson. I've listed links below to Walmart's most popular sale categories, including Christmas decor, toys, and TVs, followed by today's stand-out deals. A few highlights include Apple's all-new , this , and this Keep in mind that the deals listed below are at their lowest-ever prices, with rare discounts that you won't find outside of holiday sales like Black Friday. Walmart Black Friday sale - quick links Black Friday at Walmart: 21 editor-approved picks
Ifedi starts at left tackle for Browns in prime-time matchup against AFC North-leading Steelers
Judge grants request from prosecutors to dismiss election interference case against President-elect Donald TrumpDALLAS -- The Hilton Anatole has become Major League Baseball's top destination this week as teams converge for the winter meetings with writers, agents and even some fans circling the vast lobby floors. The biggest offseason news came down Sunday night, when the New York Mets and star free agent slugger Juan Soto reportedly agreed on a 15-year, $765 million deal, which would be the largest contract ever given to a professional athlete. That was a key talking point when managers started meeting with the media on Monday. Nationals manager Dave Martinez reflected on when he was Soto's first manager in the big leagues back in 2018. "This kid, he was different," Martinez said. "The ball comes off his bat differently. The way he approaches the hitting was way different than a lot of kids I've seen. But the one thing that I always remember about him, the first conversation I had, the first thing that came out of his mouth when I asked him what motivates him, what drives him, and he just came out and said, 'I love baseball.' Truly you can see it in him. He loves playing the game." The Red Sox were among the clubs in the mix for Soto. Boston manager Alex Cora didn't get into specific details, but he enjoyed the organization's pursuit of the four-time All Star. "It was fun in a way, you know, to get to know people and players of that status," Cora said. "It's amazing. The kid, he gets it. He gets it. Let me put it that way." Royals manager Matt Quatraro, meanwhile, spoke about the impact such a monumental contract may have on smaller market teams in order to compete in today's market. "We have to be creative. We have to put the best 26 guys on a roster or the best 40 guys on a roster, not the best one or two," Quatraro said. "At the end of the day, you have a chance to compete against those guys. Soto is going to hit four to five times a night. Those are impactful at-bats, but there's other ways to combat that with a full 26-man roster." Sasaki Posted Outside of the Soto reaction, Monday's other main storyline - at least going into the afternoon hours - centered on Japanese ace right-hander Roki Sasaki officially being posted. The 23-year-old phenom is available to sign as a free agent from Tuesday through 5 p.m. ET on Jan. 23. The rumor mill was churning with plenty of speculation and talk about where Sasaki might sign. He was just one of many big-name players being discussed on Monday. The list of top free agents behind Soto includes pitchers Corbin Burnes and Max Fried and infielders Alex Bregman, Pete Alonso and Christian Walker. On the trade front, much attention is being placed on White Sox left-handed starter Garrett Crochet. It was a relatively quiet Day 1 through the standard working hours, although things are always subject to change at meetings of this nature. Tito is Back Terry Francona joked that his desire to manage again resurfaced when his daughters went on a 10-day trip to Europe. "I watched the grandkids. That was the one day I thought maybe I'll go back to baseball," Francona said, laughing. All joking aside, Francona said it simply happened that when the Reds reached out, the timing felt right. He's healthy and refreshed as he's set to enter his 24th season as a manager. "I had a really good year and maybe I just needed that," Francona, 65, said. "Then, when these guys called, it just felt right." Honoring Mays The winter meetings kicked off with MLB announcing that its annual charity auction during the event would help revitalize Willie Mays Park in the late Hall of Famer's hometown of Fairfield, Ala. At a news conference, April Brown, MLB's senior vice president of social responsibility and diversity, said the vision for the project includes access for all levels of players, from youth leagues to advanced levels. "This effort will not just be MLB alone," Brown said. "We have the blessing of so many connected to his legacy and that have the mission to instill the love of our game that Willie had to all of the youth in the area growing up in the neighborhood where he grew up." The auction, which features items from every major league club, runs through Thursday. --Drew Davison, Field Level Media This article first appeared on Field Level Media and was syndicated with permission.
Honoring St. Nicholas
The Gunners took two points out of Liverpool’s lead at the summit of the Premier League after Jurrien Timber and William Saliba struck in the second half – both from corners – to condemn Amorim to his first defeat as United boss. The hosts’ second-half strikes took their goals-from-corners tally to 22 since the start of last season – a statistic that is unmatched by any other team in the division. Asked if Arsenal are one of the best teams he has come up against on corners, Amorim replied: “If you follow the Premier League for a long time you can see that. “They are also big players and you see every occasion when (Gabriel) Martinelli and (Bukayo) Saka have one-on-ones, a lot of times they go outside and they cross, and they know that if the cross goes well, they can score, and if it is a corner they can score, too, so we have to be better on that. “You have seen in all Arsenal games that every team have had problems with that (corners). And the difference today was the set-pieces. “You see a goal and then the momentum changed, and it is really hard for us to take the full control of the game after that.” Timber leaned into Rasmus Hojlund at the front post before diverting Declan Rice’s set-piece into the back of Andre Onana’s net after 54 minutes to send Arsenal into the lead. Thomas Partey’s header from Saka’s corner then deflected in off Saliba’s shoulder with 17 minutes left. Arteta and the club’s set-piece guru Nicolas Jover embraced on the touchline as Amorim was left with his head in his hands. The Arsenal supporters cheered raucously every time they won a corner – landing 13 in all without reply. However, Arteta moved to play down the significance of Arsenal’s set-piece threat. “We need that, but we want to be very dangerous and very effective from every angle and every phase of play,” said Arteta. “Today we could have scored from open play like we did against West Ham and Sporting. Last year we scored the most goals in the history of this football club. Arsenal have won four consecutive Premier League matches against Man Utd for the first time ever! 💫 — Premier League (@premierleague) “Not because of only set-pieces, but because of a lot of things that we have. We want to create individual and magic moments, too.” Arsenal’s win against United – the first time they have recorded four victories in a row against the Red Devils in the league – was their fourth in succession since the international break. They will head to Fulham on Sunday bidding to keep the momentum going. Arteta continued: “The will to win is there. We try our best to do that. We won four in a row, but it doesn’t matter. We have to go to Fulham now, try to be better than them and try win the game. “It’s every three days that we play. It’s a crazy schedule. We’re going to need everybody and to mentally be very strong.”Manchester United manager Ruben Amorim hailed Arsenal as one of the best set-piece teams he has ever faced following the 2-0 defeat at Arsenal. The Gunners took two points out of Liverpool’s lead at the summit of the Premier League after Jurrien Timber and William Saliba struck in the second half – both from corners – to condemn Amorim to his first defeat as United boss. The hosts’ second-half strikes took their goals-from-corners tally to 22 since the start of last season – a statistic that is unmatched by any other team in the division. Asked if Arsenal are one of the best teams he has come up against on corners, Amorim replied: “If you follow the Premier League for a long time you can see that. “You have seen in all Arsenal games that every team have had problems with that (corners). And the difference today was the set-pieces. “You see a goal and then the momentum changed, and it is really hard for us to take the full control of the game after that.” Timber leaned into Rasmus Hojlund at the front post before diverting Declan Rice’s set-piece into the back of Andre Onana’s net after 54 minutes to send Arsenal into the lead. Thomas Partey’s header from Saka’s corner then deflected in off Saliba’s shoulder with 17 minutes left. The Arsenal supporters cheered raucously every time they won a corner – landing 13 in all without reply. However, Arteta moved to play down the significance of Arsenal’s set-piece threat. “We need that, but we want to be very dangerous and very effective from every angle and every phase of play,” said Arteta. “Today we could have scored from open play like we did against West Ham and Sporting. Last year we scored the most goals in the history of this football club. “Not because of only set-pieces, but because of a lot of things that we have. We want to create individual and magic moments, too.” Arsenal’s win against United – the first time they have recorded four victories in a row against the Red Devils in the league – was their fourth in succession since the international break. They will head to Fulham on Sunday bidding to keep the momentum going. Arteta continued: “The will to win is there. We try our best to do that. We won four in a row, but it doesn’t matter. We have to go to Fulham now, try to be better than them and try win the game. “It’s every three days that we play. It’s a crazy schedule. We’re going to need everybody and to mentally be very strong.”
Blues supporters also sang the name of head coach Maresca during the closing stages of an emphatic success sealed by goals from Axel Disasi, Christopher Nkunku, Noni Madueke, Cole Palmer and substitute Jadon Sancho. Bottom club Southampton briefly levelled through Joe Aribo but were a man down from the 39th minute after captain Jack Stephens was sent off for pulling the hair of Marc Cucurella. Chelsea, who have endured an underwhelming period since Todd Boehly’s consortium bought the club in 2022, climbed above Arsenal and into second place on goal difference, seven points behind leaders Liverpool. “It was a very good feeling, especially because you can see that they are happy, that is our target,” Maresca said of the atmosphere in the away end. “We work every day to keep them happy and tonight was a very good feeling, especially the one that they can see that Chelsea’s back. This is an important thing.” Maresca rotated his squad in Hampshire, making seven changes following Sunday’s impressive 3-0 win over Aston Villa. Following a sloppy start, his side, who stretched their unbeaten run to six top-flight games, could easily have won by more as they hit the woodwork three times, in addition to squandering a host of chances. “I’m very happy with the five we scored,” said the Italian. “I’m not happy with the first 15, 20 minutes, where we struggled. The reason why we struggled is because we prepared the game to press them man to man and the first 15, 20 minutes we were not pressing them man to man. “After 15, 20 minutes we adjust that and the game was much better. For sure we could score more but five goals they are enough.” Southampton manager Russell Martin rued a costly “moment of madness” from skipper Stephens. The defender’s ridiculous red card was the headline mistake of a catalogue of errors from the beleaguered south-coast club as they slipped seven points from safety following an 11th defeat of a dismal season. “I don’t think anyone will be as disappointed as Jack,” Martin said of Stephens, who was sent off for the second time this term after tugging the curls of Cucurella as Saints prepared to take a corner. “I haven’t got to sit down and talk with him about that at all. He will be hurt more than anyone and it’s changed the game for us tonight, which is disappointing. “I think they have to describe it as violent conduct; it’s not violent really but there’s no other explanation for that really. It’s a moment of madness that’s really cost us and Jack.” Southampton repeatedly invited pressure with their risky attempts to play out from defence, with goalkeeper Joe Lumley gifting Chelsea their second goal, scored by Nkunku. While Saints were booed off at full-time, Martin, who was missing a host of key players due to injuries and suspensions, praised the effort of his depleted team. “When they see such a big scoreline and a couple of the goals we concede, I understand it (the jeers),” he said. “It’s football, it’s emotive, people feel so much about it, it’s why it’s such a special sport in this country and so big. “I understand it but I feel really proud of the players tonight, some of the football we played at 11 v 11 was amazing. “For an hour with 10 men we’ve dug in so deep, there were some big performances. I’m proud of them for that and I’m grateful for that because that’s not easy in that circumstance.”Kylian Mbappe’s spot-kick woe goes on as Real Madrid lose at Athletic Bilbao